# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Kyle Boucher maintains Bio-Techne (NASDAQ:TECH) with a Buy and raises the price target from $65 to $70.
Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target...
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...
RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue sectionTechnolog...
RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and ali...
RBC Capital analyst Conor McNamara upgrades Bio-Techne (NASDAQ:TECH) from Sector Perform to Outperform and raises the price ...